Electra CEO converts 455K preferred into common
Electra Therapeutics’ CEO converted Series A preferred into 455,484 common shares, with 73,147 subject to future vesting.
Rhea-AI Filing Summary
Electra Therapeutics, Inc. (ETRA) reported that President & CEO and director Dong Quehuong (Kathy) converted all of her Series A Convertible Preferred Stock into Common Stock on September 21, 2026 in connection with the company’s initial public offering. The conversion produced 455,484 Common shares, which she now holds directly.
Of these shares, 73,147 are Restricted Shares that vest in 13 equal monthly installments beginning September 16, 2026. The Series A Convertible Preferred Stock converted automatically into Common Stock on a one-for-one basis and had no expiration date.
Positive
- None.
Negative
- None.
Insider Trade Summary
455,484 shares exercised/converted
Exercise
2 txns
Insider
Dong Quehuong (Kathy)
Role
President & CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series A Convertible Preferred Stock F2, F1 | 455,484 | -- | -- |
| Conversion | Common Stock F1, F2 | 455,484 | -- | -- |
Holdings After Transaction:
Series A Convertible Preferred Stock — 0 contracts (Direct);
Common Stock — 455,484 shares (Direct)
Footnotes (2)
- F1. 73,147 of the shares ("Restricted Shares") shall be subject to vesting as follows: 1/13th of the Restricted Shares shall vest monthly commencing from September 16, 2026.
- F2. Each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
Key Figures
Preferred shares converted: 455,484 shares
Common shares received: 455,484 shares
Common shares held after transaction: 455,484 shares
+4 more
7 metrics
Preferred shares converted
455,484 shares
Series A Convertible Preferred Stock converted on September 21, 2026
Common shares received
455,484 shares
Common Stock acquired via conversion on September 21, 2026
Common shares held after transaction
455,484 shares
Direct ownership position following the reported conversion
Restricted Shares
73,147 shares
Portion of common shares subject to vesting
Restricted Shares vesting schedule
1/13th monthly
Monthly vesting of 73,147 Restricted Shares starting September 16, 2026
Conversion ratio
1 share of Common Stock per 1 share of Preferred Stock
Automatic conversion of Series A Convertible Preferred Stock upon IPO closing
Rule 10b5-1 plan status
No Rule 10b5-1 plan reported
Document-level indication for these transactions
Key Terms
Series A Convertible Preferred Stock, Restricted Shares, initial public offering, automatic conversion
4 terms
Series A Convertible Preferred Stock financial
"security titled Series A Convertible Preferred Stock converted automatically"
Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.
initial public offering financial
"converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
automatic conversion financial
"Each share of Series A Convertible Preferred Stock converted automatically into 1 share"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Electra Therapeutics (ETRA) report in this Form 4 for its CEO?
Electra Therapeutics reported that President & CEO Dong Quehuong (Kathy) converted all of her Series A Convertible Preferred Stock into 455,484 shares of Common Stock on September 21, 2026, related to the closing of the company’s initial public offering.
What was the conversion ratio of Electra Therapeutics’ Series A Convertible Preferred Stock?
Each share of Series A Convertible Preferred Stock converted automatically into 1 share of Common Stock upon the closing of Electra Therapeutics’ initial public offering, without any further consideration required, and the preferred stock had no expiration date.
Was this Electra Therapeutics (ETRA) Form 4 filed under a Rule 10b5-1 trading plan?
No. The document-level indication shows no Rule 10b5-1 trading plan for these transactions, and the footnotes do not describe any pre-arranged trading plan for this conversion event.
AI-generated analysis. How Rhea-AI works. Not financial advice.
